As Vaccine Revenues Flow In, BioNTech Makes Rapid Oncology Push
German Biotech Initiates Multiple IO Programs
The company also is adding new capabilities, including a cell therapy platform, and it is investing in AI and machine learning, like fellow mRNA player and COVID-19 vaccine maker Moderna.
